Eli Lilly is also pursuing another promising oral medication, orforglipron. This cutting-edge pharmaceutical treatment works to manage both Type 2 diabetes and long-term weight loss. This one-of-a-kind GLP-1 oral treatment has demonstrated remarkable promise in early-stage studies. Results indicate it may provide a less invasive and more convenient option compared to available injectable therapies.
During Phase 3 studies, more than 550 adult participants felt the positive effects of orforglipron. It totally works to bring down their hemoglobin A1C averages by a remarkable 1.3% – 1.6%. These significant reductions point to an important benefit in blood sugar control that is key to the treatment of Type 2 diabetes. On top of that, participants had noteworthy weight loss, with people losing as much as 16 pounds, or about 7.9% of their body weight.
Meanwhile, Eli Lilly is preparing to file data on orforglipron’s efficacy in chronic weight management. They intend to submit this data to the U.S. Food and Drug Administration (FDA) by the end of this year. In addition, the company plans to pursue FDA approval for its use in controlling Type 2 diabetes by early 2026.
Expressing enthusiasm at this move, David A. Ricks, chair and CEO of Eli Lilly, said, “This is historic.”
“As a convenient once-daily pill, orforglipron may provide a new option and, if approved, could be readily manufactured and launched at scale for use by people around the world,” – David A. Ricks, chair and CEO of Eli Lilly.
The safety and efficacy profile of orforglipron are similar to other injectable GLP-1s. It’s really important to note that orforglipron is not yet FDA-approved for any weight loss indications. While this incredible medication can be life-changing, it can make people feel terrible. Common side effects include constipation, diarrhea, indigestion, nausea, and vomiting.
Since its prescription debut earlier this year, orforglipron has piqued a lot of interest. Like any new medical invention, people are excited about its potential benefits — particularly for treating Type 2 diabetes. Eli Lilly is optimistic about the future of this oral medication. As science evolves and regulatory applications compile, they continue to be optimistic for its use to revolutionize diabetes care and obesity treatment efforts.
